✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Syensqo NV

Common Name
Syensqo
Country
Belgium
Sector
Basic Materials
Industry
Chemicals
Employees
13,000
Ticker
SYENS
Exchange
EURONEXT
Description
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions organization, primarily engaged in providing clinical development services. The company plays a critical role in the pharmaceu...

Syensqo's Financial Statements Preview

Below are the financial statements of Syensqo, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of EUR
2024
2023
Sales
6,846a
7,065a
Of which revenue from non-core activities
283a
231a
Of which net sales
6,563a
6,834a
Cost of goods sold
-4,627a
-4,690a
Gross profit
2,219a
2,375a
Commercial costs
-308a
-296a
Administrative costs
-697a
-521a
Research and development costs
-342a
-339a
Other operating gains and (losses)
-161a
-141a
Earnings from associates and joint ventures
21a
25a
Results from portfolio management and major restructuring
-243a
-388a
Results from legacy remediation and major litigations
-18a
-168a
EBIT
471a
547a
Cost of borrowings
-113a
-190a
Interest on loans and short term deposits
22a
81a
Other gains and (losses) on net indebtedness
-4a
-31a
Cost of discounting provisions
-18a
-28a
Result from equity instruments measured at fair value
-7a
10a
Profit/(loss) for the year before taxes
352a
389a
Income taxes
-357a
-192a
Profit/(loss) for the year
-5a
197a
Attributable to
Syensqo share
-5a
193a
Non-controlling interests
0a
3a
Net sales
6,563a
6,834a
Revenue from non-core activities
283a
231a
Raw materials, utilities and consumables used
-2,940a
-2,931a
Changes in inventories
8a
-114a
Personnel expenses
-1,525a
-1,591a
Wages and direct social benefits
-1,175a
-1,219a
Employer's contribution for social insurance
-270a
-276a
Pensions and insurance benefits
-59a
-74a
Other personnel expenses
-20a
-22a
Depreciation, amortization and impairments
-732a
-739a
Other variable logistics expenses
-209a
-181a
Other fixed expenses
-823a
-605a
Addition and reversal of provisions (excluding employee benefit obligations)
-92a
-387a
Income from cross indemnities, PFAS insurance indemnities, energy hedging novation and Edison partial award
0a
213a
M&A costs and gains and losses on disposals
-83a
-208a
Earnings from associates and joint ventures
21a
25a
EBIT
471a
547a
Limited Data Preview
You are viewing a limited preview of Syensqo’s income statement data. The reported financial values are complete. The full dataset, available for download, additionally includes structured metadata for each line item, such as line item role (line item, subtotal, total) and financial classification (e.g., assets, liabilities, equity, revenue, expenses).
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind Syensqo’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Syensqo’s data sources below and access millions more through our Disclosure Search.

a. Syensqo's Integrated Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?